['metastatic melanoma']
['sgi-110', 'ipilimumab']

        Inclusion Criteria:

          -  Willing and able to give written informed consent

          -  Unresectable Stage III or Stage IV melanoma with measurable lesions by CT or MRI per
             mWHO/irRC criteria, that can be amenable to biopsy

          -  Previously treated or untreated; prior therapy may include chemotherapy or targeted
             therapy for metastatic disease (i.e., BRAF and/or MAP-ERK kinase (MEK) inhibitor).
             Prior adjuvant interferon is permitted

          -  Subjects with Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

          -  4 weeks or greater since last treatment

          -  Must have recovered from any acute toxicity associated with prior therapy

          -  Life expectancy greater than 16 weeks

          -  Negative screening tests for HIV, Hepatitis B, and Hepatitis C

          -  Women of child-bearing potential must not be pregnant or breastfeeding, must have a
             negative pregnancy test at Screening and all men must be practicing two medically
             acceptable methods of birth control. Men should not father a child while receiving
             treatment with SGI-110 + ipilimumab, and for 2 months following completion of
             treatment. Men with female partners of childbearing potential should use effective
             contraception during this time

        Exclusion Criteria:

          -  Subjects with any contraindications for ipilimumab

          -  Subjects with active brain metastases or leptomeningeal metastases

          -  Subjects with metastatic uveal melanoma

          -  Subjects with active, known or suspected autoimmune disease

          -  Subjects with a condition requiring systemic treatment with either corticosteroids
             (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14
             days of treatment

          -  Subjects with symptomatic effusions on account of pleural, pericardial metastases of
             melanoma

          -  Prior treatment with an anti-Programmed Death receptor-1 (PD-1), anti-Programmed
             Death-1 ligand-1 (PD-L1), anti-PD-L2, or anti-CTLA-4 antibody

          -  Subjects who had major surgery or radiation therapy within 21 days of starting
             treatment

          -  Subjects who are unable to return for follow-up visits as required by this study

        Other Exclusion Criteria:

          -  Prisoners or subjects who are involuntarily incarcerated

          -  Subjects who are compulsorily detained for treatment of either a psychiatric or
             physical (e.g., infectious disease) illness.
      